Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) have received a consensus recommendation of “Buy” from the ten analysts that are currently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $89.89.
ARWR has been the subject of a number of research reports. Chardan Capital lowered their target price on Arrowhead Pharmaceuticals from $97.00 to $94.00 and set a “buy” rating for the company in a research note on Friday, August 6th. SVB Leerink upped their price target on Arrowhead Pharmaceuticals from $44.00 to $45.00 and gave the stock a “market perform” rating in a research report on Tuesday. HC Wainwright upped their price target on Arrowhead Pharmaceuticals from $95.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, August 10th. Finally, TheStreet raised Arrowhead Pharmaceuticals from a “d+” rating to a “c-” rating in a report on Thursday, November 4th.
Shares of ARWR stock traded up $3.15 on Thursday, reaching $74.04. The company had a trading volume of 590,632 shares, compared to its average volume of 741,581. The stock has a market cap of $7.72 billion, a PE ratio of -60.20 and a beta of 1.14. The company has a 50-day moving average of $67.29 and a 200-day moving average of $69.47. Arrowhead Pharmaceuticals has a 12 month low of $56.05 and a 12 month high of $93.66.
In related news, insider Martin Javier San sold 19,500 shares of the firm’s stock in a transaction on Friday, November 19th. The stock was sold at an average price of $69.31, for a total value of $1,351,545.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Christopher Richard Anzalone sold 15,000 shares of the firm’s stock in a transaction on Wednesday, October 20th. The stock was sold at an average price of $66.23, for a total value of $993,450.00. The disclosure for this sale can be found here. Insiders have sold a total of 89,500 shares of company stock worth $5,945,295 in the last quarter. Company insiders own 3.50% of the company’s stock.
Several institutional investors have recently bought and sold shares of ARWR. Itau Unibanco Holding S.A. bought a new stake in Arrowhead Pharmaceuticals in the second quarter worth approximately $26,000. Point72 Hong Kong Ltd increased its holdings in Arrowhead Pharmaceuticals by 108.2% in the first quarter. Point72 Hong Kong Ltd now owns 683 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 355 shares in the last quarter. Sound Income Strategies LLC increased its holdings in Arrowhead Pharmaceuticals by 36.8% in the second quarter. Sound Income Strategies LLC now owns 930 shares of the biotechnology company’s stock worth $77,000 after purchasing an additional 250 shares in the last quarter. IronBridge Private Wealth LLC increased its holdings in Arrowhead Pharmaceuticals by 109.9% in the second quarter. IronBridge Private Wealth LLC now owns 955 shares of the biotechnology company’s stock worth $79,000 after purchasing an additional 500 shares in the last quarter. Finally, Assetmark Inc. bought a new stake in Arrowhead Pharmaceuticals in the third quarter worth approximately $84,000. 63.54% of the stock is currently owned by institutional investors.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by R.
Featured Article: What moving averages are used to define a golden cross?
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.